InSightec Exablate coverage expands to 99.8million US individuals

757

 

InSightec Exablate platform
InSightec Exablate platform

Coverage for Exablate (InSightec) for pain palliation of bone metastases in cancer patients has expanded for members of a major health insurance provider in the USA.

This expansion of coverage means that a total of 99.8 million members across the USA now have access to MRgFUS for palliative care of painful bone metastases.

“This coverage decision is a huge win for our cancer patients suffering with bone pain,” says Sean M Tutton, director at the Division of Interventional Radiology and Professor of Radiology, Palliative Medicine, and Surgery at the Medical College of Wisconsin (Milwaukee, USA). “MRgFUS has proven to be an effective totally non-invasive treatment in reducing pain and narcotic needs even in patients that have failed radiation already,” he concluded.

“We are encouraged as more patients gain access to this non-invasive treatment which uses no radiation to control their painful metastases,” says Dee Kolanek, vice president of Reimbursement at InSightec.